The weekly litigation news digest is live. Subscribe now

IP Verse

Methods Of Treating Inflammatory And Autoimmune Diseases With Natalizumab - EP2676967

The patent EP2676967 was granted to Biogen Idec MA on Aug 14, 2019. The application was filed on Feb 28, 2007 under application number EP13175987A. The patent is currently recorded with a legal status of "Revoked".

EP2676967

BIOGEN IDEC MA
Application Number
EP13175987A
Filing Date
Feb 28, 2007
Status
Revoked
Feb 17, 2023
Publication Date
Aug 14, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
POLPHARMA BIOLOGICSMay 14, 2020WICHMANN -

Patent Citations (5) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2002197233
DESCRIPTIONUS5840299
DESCRIPTIONUS6033665
DESCRIPTIONUS6551593
DESCRIPTIONUS6602503

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents